Eliana Stanganello

Karlsruhe Institute of Technology — Germany

Medicine · Health Sciences

9h-index710citations26works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(7), CAR-T cell therapy research(6), Cancer Immunotherapy and Biomarkers(4), Wnt/β-catenin signaling in development and cancer(4), Immunotherapy and Immune Responses(3)

Publications26 total

Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions
2025
Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer
Blood Advances·2023· 12 citedOpen Access
Protocol for the murine antibody-dependent cellular phagocytosis assay
Methods in cell biology·2022· 1 cited
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Journal for ImmunoTherapy of Cancer·2022· 36 citedOpen Access
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Cancer Discovery·2022· 104 citedOpen Access
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Cancer Immunology Immunotherapy·2021· 24 citedOpen Access
Abstract 1846: DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions <i>in vitro</i> by conditional CD40 and 4-1BB agonist activity
Cancer Research·2021· 2 cited
Wnt Signaling Directs Neuronal Polarity and Axonal Growth
iScience·2019· 37 citedOpen Access
3D Simulations of Morphogen Transport in an Early Fish Embryo
Biophysical Journal·2016
page 1 of 2Next →

Frequent Co-authors

Fulvia Vascotto(16), Mustafa Diken(15), Özlem Türeci(15), Alexander Muik(14), Işıl Altıntaş(14), Friederike Gieseke(14), Saskia M. Burm(14), Aras Toker(14), Mark Fereshteh(14), Sebastian Kreiter(14), Esther C.W. Breij(14), Kate Sasser(14), Tahamtan Ahmadi(14), Maria Jure‐Kunkel(14), Uğur Şahin(14), Kristina B. Schoedel(13), Jordan M. Blum(13), Bianca Sänger(13), Dennis Verzijl(13), Juliane Quinkhardt(13)